Home » BioMS Multiple Sclerosis Drug Fails Mid-Stage Study
BioMS Multiple Sclerosis Drug Fails Mid-Stage Study
Canada’s BioMS Medical Corp said its lead drug for the treatment of multiple sclerosis failed to meet the main goal of a mid-stage study.
Interactive Investor
Interactive Investor
Upcoming Events
-
07May
-
14May
-
30May